GlassScriptPhysician profile
Christopher Ian Earle
NPI 1003242314
$2,927.13
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $599 · 2022: $1,530 · 2023: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $670.93 | 2021-2023 | |
| Abbvie INC. | $520.39 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $420.67 | 2021-2023 | Spravato |
| Almatica Pharma LLC | $365.09 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Otsuka America Pharmaceutical, INC. | $268.32 | 2022-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $204.43 | 2021-2022 | |
| Indivior INC. | $147.71 | 2021-2023 | Sublocade |
| Alkermes, INC. | $143.00 | 2021-2023 | Lybalvi |
| Corium, LLC | $48.54 | 2023 | Azstarys, Azstarys |
| Idorsia Pharmaceuticals US INC | $37.59 | 2022-2023 | Quviviq |
| Neuronetics, INC. | $34.59 | 2023 | Neurostar Tms Therapy System |
| Uswm, LLC | $19.64 | 2021 | |
| Lundbeck LLC | $16.85 | 2022 | |
| Eisai INC. | $15.62 | 2021 | |
| Axsome Therapeutics, INC. | $13.76 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Earle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.